---
title: "Tevogen Bio (TVGN.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TVGN.US/norm.md"
symbol: "TVGN.US"
name: "Tevogen Bio"
parent: "https://longbridge.com/en/quote/TVGN.US.md"
datetime: "2026-05-21T13:43:18.829Z"
locales:
  - [en](https://longbridge.com/en/quote/TVGN.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TVGN.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TVGN.US/norm.md)
---

# Tevogen Bio (TVGN.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -1.61 | -2.35 | -1.50 | -1.53 | -3.25 |
| ROE | 126.05% | 114.51% | 134.35% | 129.66% | 262.65% |
| Revenue | - | - | - | - | - |
| Net income | -5.62M | -4.82M | -5.86M | -5.64M | -10.50M |
| Operating income | -5.40M | -4.61M | -5.73M | -5.44M | -10.36M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 4.92M | 4.38M | 4.49M | 4.27M | 4.07M |
| Leverage | -0.5000 | -0.5323 | -0.5744 | -0.4501 | -0.5276 |
| BVPS | -4.47 | -4.24 | -4.21 | -4.72 | -4.49 |
| Turnover | - | - | - | - | - |
| Cash & STI | 692305.00 | 552372.00 | 1.04M | 685229.00 | 1.97M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 1.53M | 1.59M | 1.62M | 1.64M | 419530.00 |
| Net debt | 8.78M | 6.95M | 6.49M | 6.87M | 2.85M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.73M | -2.18M | -3.65M | -3.19M | -3.31M |
| Investing CF | - | -64439.00 | - | - | - |
| Financing CF | 2.87M | 1.76M | 4.00M | 1.90M | 4.00M |
| Free CF | -728171.00 | 14286.00 | -1.36M | -940391.00 | 635877.00 |
| OCF coverage | - | -3385.01% | - | - | - |
| Repaid & issued | 2.00M | 0.0000 | 0.0000 | 1.40M | 2.00M |
| CapEx | - | -64439.00 | - | - | - |